Form 4: TG Therapeutics Director Kenneth Hoberman Receives Significant Restricted Stock Grant

TG Therapeutics Director Kenneth Hoberman was granted 14,718 shares of restricted common stock on June 12, 2025, increasing his total beneficial ownership to 279,653 shares.

Summary

• Kenneth Hoberman, a Director of TG Therapeutics, Inc. (TGTX), acquired 14,718 shares of Common Stock.
• The transaction occurred on June 12, 2025.
• These shares were granted at a price of $0, indicating a restricted stock grant.
• The newly acquired shares will vest on June 12, 2026.
• Following this transaction, Mr. Hoberman's total beneficial ownership of TG Therapeutics Common Stock is 279,653 shares.
• This total includes other restricted Common Stock that vests over various time periods.

Sentiment

Score: 7

Explanation: The grant of restricted shares to a director is a positive signal of alignment between management and shareholder interests, as it ties the director's compensation to the company's long-term stock performance. This is a routine and expected form of compensation.

Positives

• The grant of restricted shares to Director Kenneth Hoberman aligns his interests with long-term shareholder value, as the shares vest over time.
• An increase in insider ownership, even through grants, can signal confidence in the company's future prospects.

Risks

• The value of the granted shares is subject to the future performance of TG Therapeutics' stock price.
• The shares are restricted and do not fully vest until June 12, 2026, meaning the director cannot sell them immediately.

Future Outlook

This filing primarily details an insider stock grant and does not contain forward-looking statements regarding the company's operational or financial outlook, beyond the vesting schedule of the granted shares.

Industry Context

This Form 4 filing details a standard compensation practice within publicly traded companies, particularly in the biotechnology sector, where equity grants are a common component of executive and director remuneration to align interests with long-term company performance.

Related Party Transactions

• The grant of restricted shares to Director Kenneth Hoberman constitutes a related party transaction, which is a standard form of equity compensation for board members.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of director's interests with long-term stock performance.

Next Steps

• Vesting of the 14,718 restricted shares on June 12, 2026.
• Continued beneficial ownership of 279,653 shares, including other restricted stock vesting over various periods.

Key Dates

Recommendation

Keywords

TG Therapeutics, TGTX, Kenneth Hoberman, Form 4, insider trading, restricted stock, stock grant, beneficial ownership, director compensation